Use of tadalafil as protein arginine methyltransferase (PRMT5) inhibitor
US11369602B2 · kind B2 · utility
0Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 2, 2020 |
| Grant date | Jun 28, 2022 |
| Priority date | — |
| Expiry date | Feb 9, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/7048
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides use of Tadalafil as a protein arginine methyltransferase 5 (PRMT5) inhibitor. The present invention finds out that Tadalafil is a PRMT5 inhibitor by virtually screening active compounds targeting PRMT5 based on crystal structure and information about active sites of PRMT5. The present invention not only confirms that Tadalafil can inhibit an enzymatic activity of PRMT5, but also confirms that Tadalafil alone can inhibit tumor growth in breast cancer and improve sensitivity to chemotherapy for breast cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.